Saturable Binding of Finasteride to Steroid 5α-reductase as Determinant of Nonlinear Pharmacokinetics

    January 2010 in “Drug Metabolism and Pharmacokinetics
    Rie Suzuki, Hiroki Satoh, Hisakazu Ohtani, Satoko Hori, Yasufumi Sawada
    Image of study
    TLDR Finasteride's effect on hair loss and prostate enlargement depends on its binding to an enzyme, with maximum impact at 0.2 mg dose.
    This study investigated the pharmacokinetics and pharmacodynamics of finasteride, a drug used to treat hair loss and prostate enlargement. The study found that the drug's binding to steroid 5α-reductase, an enzyme involved in the production of dihydrotestosterone (DHT), is a determinant of its nonlinear pharmacokinetics. The study also found that the drug's inhibition of 5αR1 is negligible in the dose range up to 1 mg, and that the serum DHT-reducing effect of finasteride reaches its maximum at a dose of 0.2 mg in the case of repeated administration. The study concludes that the time-dependent increase in AUC observed during repeated oral administrations of finasteride may be explained by the saturation of finasteride binding to 5αR2.
    View this study on sciencedirect.com →

    Cited in this study

    Related